Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors
Bioorganic & Medicinal Chemistry Letters · 2023
DOI: 10.1016/j.bmcl.2023.129352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023. Verfasst von Neil P Grimster und 36 weiteren Autor:innen. Beteiligte Einrichtung: Oncology R & D, AstraZeneca, Waltham, USA. Electronic address: neil.grimster@astrazeneca.com. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Signal Transduction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Spleen tyrosine kinase (SYK) is a non-receptor cytoplasmic kinase. Due to its pivotal role in B cell receptor and Fc-receptor signalling, inhibition of SYK has been a target of interest in a variety of diseases. Herein, we report the use of structure-based drug design to discover a series of potent macrocyclic inhibitors of SYK, with excellent kinome selectivity and in vitro metabolic stability. We were able to remove hERG inhibition through the optimization of physical properties, and utilized a pro-drug strategy to address permeability challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology R & D, AstraZeneca, Waltham, USA. Electronic address: neil.grimster@astrazeneca.com.
- Oncology R & D, AstraZeneca, Waltham, USA.
- Oncology R & D, AstraZeneca, Cambridge, UK.
- Discovery Sciences R & D, AstraZeneca, Waltham, USA.
- Discovery Sciences R & D, AstraZeneca, Cambridge, UK.
- Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China.
Zitieren
APA
Grimster, N. P., Gingipalli, L., Balazs, A., Barlaam, B., Boiko, S., Boyd, S., Dry, H., Goldberg, F. W., Ikeda, T., Johnson, T., Kawatkar, S., Kemmitt, P., Lamont, S., Lorthioir, O., Mfuh, A., Patel, J., Pike, A., Read, J., Romero, R., …, & Edmondson, S. D. (2023). Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2023.129352
Vancouver
Grimster NP, Gingipalli L, Balazs A, Barlaam B, Boiko S, Boyd S, et al. Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors. Bioorganic & Medicinal Chemistry Letters. 2023. doi:10.1016/j.bmcl.2023.129352
BibTeX
@article{Grimster2023,
author = {Grimster, Neil P and Gingipalli, Lakshmaiah and Balazs, Amber and Barlaam, Bernard and Boiko, Scott and Boyd, Scott and Dry, Hannah and Goldberg, Frederick W and Ikeda, Tim and Johnson, Tony and Kawatkar, Sameer and Kemmitt, Paul and Lamont, Scott and Lorthioir, Olivier and Mfuh, Adelphe and Patel, Joe and Pike, Andy and Read, Jon and Romero, Romulo and Sarkar, Ujjal and Sha, Li and Simpson, Iain and Song, Kun and Su, Qibin and Wang, Haixia and Watson, David and Wu, Allan and Zehnder, Troy E and Zheng, XiaoLan and Li, Shaolu and Dong, Zhiqiang and Yang, Dejian and Song, Yanwei and Wang, Peng and Liu, Xuemei and Dowling, James E and Edmondson, Scott D},
title = {Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2023},
doi = {10.1016/j.bmcl.2023.129352}
}
EUVIMED